Migraine therapies are designed to alleviate symptoms or prevent future episodes in migraine sufferers. The rising frequency of migraines problems around the world, as well as increased awareness of novel drug classes, are driving the expansion of the migraine market. The introduction of calcitonin gene-related peptide (CGRP) is also predicted to boost the industry's growth. Migraine headaches are characterised by a strong and recurrent headache, as well as phonophobia, photophobia, and nausea. The disorder is caused by hereditary factors. Migraine episodes can be triggered by emotional imbalances such as despair, stress, worry, shock, and enthusiasm. There have been a variety of drug options for preventing and treating migraines, but they all have serious side effects, such as weight gain, dizziness, nausea, and more in an adult with no underlying medical conditions. Sumatriptan is the safest therapeutic option for pregnant women, and anticonvulsant medications are not recommended. However, the approval of a new class of medicine specifically developed to treat migraines by the US Food and Drug Administration has had a favourable impact on the market. Aimovig (Erenumab), Emgality, and Ajovy are the three new FDA-approved medications. Emgality (galcanezumab-gnlm), a 120 mg injectable for the preventative treatment of migraine in adults, was approved by the US Food and Drug Administration (FDA) in September 2018.

Region Analysis:

Geographically, North America dominates the market. According to the American Migraine Association, migraine affects over 36 million Americans, or around 12% of the people in the region. The market is expected to rise due to increased vendor focus on growing markets such as Asia-Pacific, Latin America, and the Middle East and Africa. Moreover, due to rising demand for better healthcare services and strengthened healthcare infrastructure, Asia-Pacific is expected to see significant growth in the future. Due to increased demand for better healthcare facilities and advances in healthcare infrastructure, Asia-Pacific is expected to grow significantly in the future. Furthermore, because the developed markets are somewhat saturated, this region presents exceptional potential for venture capitalists and investors.

Key Development:

• On 2022, The European Medicines Agency (EMA) has given rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, a positive opinion, recommending the 75 mg dose of rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without a headache.
• In 2022, ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults, was launched and made available in the United States today by BioDelivery Sciences International, Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/833

Segmentation:

Migraine Drugs Market accounted for US$ 2.2 billion in 2020 and is estimated to be US$ 8.3 billion by 2030 and is anticipated to register a CAGR of 15.70%. The market report has been segmented on the basis of treatment, route of administration, distribution channel, and region.

• By treatment, the migraine drugs market is segmented into abortive or acute and prophylactic or preventive. Abortive or acute sub-segment is categorized into triptans, ergot alkaloids, and anti-nausea medications. Further, prophylactic or preventive sub-segment is bifurcated into botulinum toxin, topiramate, and glucocorticoids.
• By route of administration, the migraine drugs market is classified into oral, injectable, and others. Others route of administration sub-segment is nasal spray and transdermal patch.
• By distribution channel, the migraine drugs market is categorized into retail pharmacies, hospital pharmacies, and online pharmacies.
• By region, North America migraine drugs market is expected to account for major revenue share in migraine drugs market, followed by other regions. This is attributed to rising penetration of migraine in the countries of the North America region. The Asia Pacific migraine drugs market is emerging market in the migraine drugs market in 2018.

Competitive Analysis:                                                                                                 

The prominent player operating in the migraine drugs market includes Pfizer Inc, GlaxoSmithKline plc, Allergan plc, Amgen Inc, Eli Lilly and Company, Teva Pharmaceuticals USA, Inc, Biohaven Pharmaceutical Holding Company Ltd, Johnson & Johnson, Novartis Pharmaceuticals Canada Inc., and Alembic Pharmaceuticals Limited.